Success Metrics

Active Trials
3(100%)

Phase Distribution

Ph phase_2
1
33%
Ph phase_3
2
67%

Phase Distribution

0

Early Stage

1

Mid Stage

2

Late Stage

Phase Distribution3 total trials
Phase 2Efficacy & side effects
1(33.3%)
Phase 3Large-scale testing
2(66.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

3

trials recruiting

Total Trials

3

all time

Status Distribution
Active(3)

Detailed Status

Active, not recruiting3

Development Timeline

Analytics

Development Status

Total Trials
3
Active
3
Success Rate
N/A
Most Advanced
Phase 3

Trials by Phase

Phase 21 (33.3%)
Phase 32 (66.7%)

Trials by Status

active_not_recruiting3100%

Recent Activity

3 active trials
Showing 3 of 3
active_not_recruitingphase_2

TSR-042 as Maintenance Therapy for Patients With High-risk Locally Advanced Cervical Cancer After Chemo-radiation

NCT03833479
active_not_recruitingphase_3

PET Scan in Planning Treatment in Patients Undergoing Combination Chemotherapy For Stage IA or Stage IIA Hodgkin Lymphoma

NCT00943423
active_not_recruitingphase_3

Trial of Immunomodulatory Therapy in High Risk Solitary Bone Plasmacytoma

NCT02544308

Clinical Trials (3)

Showing 3 of 3 trials
NCT03833479Phase 2

TSR-042 as Maintenance Therapy for Patients With High-risk Locally Advanced Cervical Cancer After Chemo-radiation

Active Not Recruiting
NCT00943423Phase 3

PET Scan in Planning Treatment in Patients Undergoing Combination Chemotherapy For Stage IA or Stage IIA Hodgkin Lymphoma

Active Not Recruiting
NCT02544308Phase 3

Trial of Immunomodulatory Therapy in High Risk Solitary Bone Plasmacytoma

Active Not Recruiting

All 3 trials loaded

Drug Details

Intervention Type
OTHER
Total Trials
3